Pluri (DB:4DX) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

4DX Panoramica delle azioni

A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.

Informazioni sull'azienda

4DX analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 3.6% all'anno negli ultimi 5 anni

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $341K )

Le azioni sono altamente illiquide

Non ha una capitalizzazione di mercato significativa ( €27M )

Gli azionisti sono stati diluiti nell'ultimo anno

Pluri Inc. Concorrenti

2invest

XTRA:2INV

€59.8m

Medigene

XTRA:MDG1

€27.6m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€124.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Pluri
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$5.60
Massimo di 52 settimane	US$7.32
Minimo di 52 settimane	US$3.10
Beta	1.62
1Variazione di 1 mese	0%
Variazione a 3 mesi	-10.83%
Variazione di 1 anno	1.45%
3Variazione a 3 anni	-79.24%
Variazione a 5 anni	-86.89%
Variazione dall'IPO	-76.74%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	4DX	DE Biotechs	DE Mercato
7D	0%	0.7%	1.1%
1Y	1.4%	-8.5%	18.9%

Ritorno vs Industria: 4DX ha superato il German Biotechs che ha restituito -22 % nell'ultimo anno.

Rendimento vs Mercato: 4DX ha avuto una performance inferiore al mercato German che ha registrato un rendimento 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is 4DX's price volatile compared to industry and market?
4DX volatility
4DX Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di 4DX è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 4DX nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2001	129	Yaky Yanay	www.pluri-biotech.com

Pluri Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Pluri con la sua capitalizzazione di mercato?
4DX statistiche fondamentali
Capitalizzazione di mercato	€24.83m
Guadagni(TTM)	-€20.13m
Ricavi(TTM)	€317.54k

78.2x

Rapporto P/S

-1.2x

Rapporto P/E

4DX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
4DX Conto economico (TTM)
Ricavi	US$341.00k
Costo del fatturato	US$9.00k
Profitto lordo	US$332.00k
Altre spese	US$21.95m
Guadagni	-US$21.62m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-4.01
Margine lordo	97.36%
Margine di profitto netto	-6,339.59%
Rapporto debito/patrimonio netto	1,304.3%

Come si è comportato 4DX nel lungo periodo?

Vedi performance storica e confronto

4DX Panoramica delle azioni

Premi

Analisi del rischio

Pluri Inc. Concorrenti

XTRA:2INV

€59.8m

XTRA:MDG1

€27.6m

XTRA:CNW

€6.5m

XTRA:HPHA

€124.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Recent updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

High number of new directors

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought €126k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Independent Director Isaac Braun has left the company

Insider recently sold €1.3m worth of stock

Insider recently sold €84k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

New 90-day low: €4.30

Revenue in line with expectations

Pluristem Therapeutics Inc. Announces Board Appointments

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

New 90-day high: €9.75

Insider recently bought €162k worth of stock

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

New 90-day low: €7.20

Revenue in line with expectations

Insider recently bought €158k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

New 90-day high: €9.40

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought €269k worth of stock

Full year earnings released - €1.60 loss per share

New 90-day high - €9.30

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Pluri Inc. Riepilogo dei fondamenti

78.2x

-1.2x

Guadagni e ricavi